There are 360 resources available
185P - Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
Presenter: Wolfgang Wick
Session: Poster Display
79P - Efficacy and Safety of Zimberelimab (GLS-010) Monotherapy in Patients with Recurrent or Metastatic CervicalCancer: A Multicenter, Open-Label, Single-Arm, Phase II Study
Presenter: Xiaohua Wu
Session: Poster Display
186P - Synergistic antitumor effect of gemcitabine combined with Nyeso1-vaccine treatment evaluated in mouse PDAC organoids
Presenter: Nathalia Ferreira
Session: Poster Display
187P - Phase 1/2 study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer
Presenter: Chia-Chi Lin
Session: Poster Display
81P - Is PD-1 inhibitor based treatment better than chemotherapy for metastatic NSCLC patients with PD-L1≥50% who develop EGFR-TKI resistance? A real-world investigation
Presenter: Yujing Li
Session: Poster Display
188P - IPH5201 as Monotherapy or in Combination with Durvalumab (D) in Advanced Solid Tumours
Presenter: Martina Imbimbo
Session: Poster Display
82P - Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)
Presenter: Ting Wang
Session: Poster Display
189P - IL-10 enhances macrophage phagocytosis of cancer cells in response to CD47 blockade and opsonizing antibodies
Presenter: Asaf Maoz
Session: Poster Display
83P - The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies ÒpureÓ IRAEs strongly associated with outcome in a phase 1-2 trial population
Presenter: Luca Mazzarella
Session: Poster Display